These were the main conclusions drawn from a single-centre study that aimed to assess histological activity using the validated Nancy histological activity score as a predictor of future relapse [1]. Enrolled were 74 ulcerative colitis patients in both clinical and endoscopic remission attending a tertiary centre in Canberra, Australia, between 2015 and 2018. Clinical remission was defined as partial Mayo score (MSp) <2, and endoscopic remission was defined as Mayo Endoscopic Subscore (MES) ≤1. Median follow-up was 42 months, the median relapse free period 30 months.
Patients with MES 0 (P=0.02) and histological remission (P≤0.0001) had a significantly longer relapse free survival. Multivariate analysis showed that histological activity was the only independent risk factor of future clinical relapse (HR 4.36, 95% CI 1.68-11.27; P=0.002). The authors added that long-term prospective studies will need to determine whether histological remission improves clinical and patient-reported outcomes.
- Wang H, et al. ECCO 2019, DOP68.
Posted on
Previous Article
« Gene expression signature predicts non-response Next Article
Tofacitinib: Results from the OCTAVE open-label studies »
« Gene expression signature predicts non-response Next Article
Tofacitinib: Results from the OCTAVE open-label studies »
Table of Contents: ECCO 2019
Featured articles
Interview with Prof. Janneke van der Woude
New Compounds: Study Results
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Complementary and Alternative Medicine
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Microbial composition and psychological wellbeing
Remission
Early remission of Crohn’s disease prevents progression
Proactive adalimumab trough measurements
Observational Studies
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Immune cells and microbes: a happy marriage?
Genetics
Related Articles
May 9, 2019
The right drug for the right patient
May 9, 2019
Molecular effects of ustekinumab
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy